203 results about "Controlled drugs" patented technology

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

The invention discloses a drug targeted delivery device and method, and belongs to the technical field of intelligent medical treatment. The device comprises the following modules: an intelligent targeted recognition module for accurately recognizing a gastric cancer specific molecular marker and improving the selectivity and specificity of targeted recognition in combination with a dynamic surface modification strategy; the microenvironment real-time monitoring module is used for monitoring key physiological parameters of the gastric cancer microenvironment in real time; the intelligent path planning module is used for dynamically calculating and optimizing a drug delivery path and realizing accurate drug positioning; the personalized drug administration regulation and control module is used for accurately predicting the drug dosage demand of an individual and dynamically and finely adjusting the drug administration amount in real time; the drug resistance risk management module is used for early warning a drug resistance risk in advance and automatically generating a personalized alternative drug administration strategy through multi-dimensional drug resistance analysis and real-time early warning; and the intelligent drug release module adopts a temperature-sensitive / pH-sensitive polymer shell layer and a nano valve to control drug release, so that precise gradient release of drug concentration is realized.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a 2-aminopyrimidine compound, application thereof and an antitumor drug. The 2-aminopyrimidine compound provided by the invention has a structure as shown in a formula (I). According to the invention, 2-aminopyrimidine is used as a mother nucleus structure, and a series of 2-aminopyrimidine compounds are successfully constructed by accurately introducing a biologically active imidazole, thiazole or oxazole nitrogen-containing heterocyclic ring fragment at the 5 # site of 2-aminopyrimidine; systematic in-vitro anti-tumor activity evaluation proves that the 2-aminopyrimidine compound with the structure as shown in the formula (I) provided by the invention shows remarkable inhibitory activity on various tumor cell lines, and the activity of part of the compound is even superior to that of a clinical control drug. The structural diversity of 2-aminopyrimidine compounds is enriched, valuable lead compounds are provided for developing novel efficient antitumor drugs, and the 2-aminopyrimidine compounds have important scientific significance and clinical transformation potential. # imgabs0 #

The invention relates to the technical field of biology, in particular to silymarin inclusion compound lipidosome and a preparation method and application thereof. The silymarin inclusion compound liposome is prepared from the following components in parts by weight: 10 to 48 parts of silymarin, 10 to 53 parts of phospholipid, 5 to 10 parts of Arabic gum and 25 to 70 parts of cyclodextrin. According to the invention, cyclodextrin and phospholipid are combined to form a double-drug-loading structure; on the basis, Arabic gum is used as a film-forming agent to form a protective film on the surface of the liposome, so that the stability of the system is further improved; the silymarin inclusion compound is encapsulated in a water phase in the liposome, and meanwhile, part of free silymarin is encapsulated in a lipid bilayer. According to the structure, the solubility and the encapsulation efficiency of the silymarin are remarkably improved, the liposome stability is enhanced, the drug release is effectively controlled, and the silymarin inclusion compound lipid is simple in preparation process and suitable for industrial production.

The invention discloses a self-driven diagnosis and treatment integrated microneedle array paper-based chip as well as a preparation method and application thereof, and belongs to the technical field of biomedicine. The microneedle array chip system comprises a function integration module which at least comprises a self-powered extraction unit, a sensing detection unit and a controlled drug delivery unit. According to the microneedle array paper-based chip, biomarkers in skin interstitial fluid are efficiently collected based on a self-powered thermoelectric chemical battery microneedle, PtPB (at) PEG (at) HA nanoparticles loaded on an immunochromatography test strip combination pad are triggered to be subjected to ring opening, a hybridization chain reaction is induced to generate DNA nano-enzyme, and TMB is catalyzed to develop color; the open-loop nanoparticles can be used for SERS cross detection of biomarkers, and can be used as a thermal initiator to activate the phase change microneedle under the irradiation of near-infrared light, so that drugs are released as required, and precise treatment is realized. Besides, objective quantitative analysis of color signals is realized by constructing a convolutional neural network model, and the system has the functions of naked eye screening, intelligent quantification and personalized treatment, and can improve the home management ability of early skin cancer.

The present invention discloses a light-responsive Pickering emulsion that is synergistically stabilized by a spiropyran ionic liquid and UiO-66-NH2. The Pickering emulsion comprises an oil-water phase, and its stabilizer is a spiropyran ionic liquid and a metal-organic framework material UiO-66-NH2. The stable Pickering emulsion can undergo demulsification under additional visible light irradiation. When further irradiated with ultraviolet light, the system can be re-emulsified to form a stable Pickering emulsion. The Pickering emulsion provided by the present invention can be used for the Click reaction of hydrophilic azide compounds and terminal alkynyl compounds. Through reversible visible light and ultraviolet light regulation, the catalyst and spiropyran ionic liquid can be recycled, and the Pickering emulsion has application value in the fields of controlled drug release and sustainable catalysis.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

The present application discloses an antibacterial hydrogel dressing with integrated constant temperature photothermal effect and controlled drug release function, as well as its preparation method and application, which belongs to the field of medical biomaterial technology. The antibacterial hydrogel dressing with integrated constant temperature photothermal effect and controlled drug release function provided by the present application includes: a dressing and an antibiotic drug compounded on the dressing; the dressing is woven from photothermal water gel fiber and thermosensitive hydrogel fiber; the photothermal water gel fiber is made of photothermal dye, proton donor and phase change material as the core layer and sodium alginate as the shell layer; the thermosensitive hydrogel fiber is made of N-isopropyl acrylamide, methylene bisacrylamide, phenyl-2,4,6-trimethylbenzoyl lithium phosphinate and sodium alginate. The hydrogel dressing prepared by the present application has an inherent temperature control mechanism, can release drugs on demand and in a concentrated manner, has excellent antibacterial effect, and has broad application prospects in the preparation of biomedical materials.

The invention discloses a thiochromanone derivative containing a thiosemicarbazone structure and application of the thiochromanone derivative, relates to the technical field of medicines, and particularly relates to the technical field that the compound has better oxidation resistance and alpha-glucosidase resistance activity, the IC50 value of the compound 1-(7-chloro-4, 4-dioxothiochromanone-3-N-propyl) thiosemicarbazone to ABTS clearance activity is 2.86 [mu] g / mL, the IC50 value of the compound 1-(7-chloro-4, 4-dioxothiochromanone-3-N-propyl) thiosemicarbazone to alpha-glucosidase inhibition activity is 9.51 [mu] g / mL, and the effect is the best and is superior to that of a control agent vitamin E and acarbose. The thiochromanone derivative containing the thiosemicarbazone structure has a general formula shown in the specification,

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

This invention arrests the hydrophilic silicone macrochains into semi-interpenetrating polymer network via in situ photo-gelation assisted 3D microextrusion printing technique. The printed hybrid hydrogel has shown microporous morphology with tunable diffusion behaviour. The flow behaviour of the hydrogel has been tested showing high elastic modulus, low tan δ, high gel strength, and delayed network rupturing behaviour. The uniaxial compression test showed the almost zero permanent set which could promote it as an elastomer mimetic soft biomaterial. Moreover, the drug loading into the hydrogel has been performed which showed hydrophilic silicone dependent non-Fickian anomalous transport. The encapsulated drug stability inside hydrogel matrices also showed no deterioration of the pristine drug molecules even after one month storage. This could be the first hydrodrophilic silicone based soft biomaterial will serve as an excellent controlled drug delivery device.

The present invention belongs to the field of biomedical materials and specifically relates to anti-tumor nanoparticles, their preparation methods, and applications. The present invention claims protection for an anti-tumor nanoparticle comprising compound PTe N25, wherein the nanoparticles are simultaneously encapsulated with a camptothecin compound and compound PTe N25 using a phospholipid. The structural formula of compound PTe N25 is: #imgabs0# The present invention utilizes cRGD and camptothecin compounds in conjunction with an organic conjugated polymer material to prepare a dual-targeted chemotherapy-photothermal therapy combined treatment system. This system achieves cRGD-targeted recognition of cancer cells, controlled drug release responsive to spatiotemporal light dual stimulation in the context of a diseased environment, and integrated chemotherapy and photothermal therapy synergistic treatment, significantly reducing drug toxicity and side effects while maintaining anti-tumor efficacy.

The invention relates to the technical field of organic chemistry, and particularly discloses an amide derivative containing a thiazole oxime structure as shown in a general formula 8 and a preparation method and application of the amide derivative. The derivative shows remarkable antibacterial activity on staphylococcus aureus, escherichia coli, pseudomonas aeruginosa and fluoroquinolone-resistant escherichia coli, particularly has a remarkable effect on gram-negative bacteria, has broad-spectrum antibacterial potential and can be used for preparing drugs for treating related bacterial infection, and the activity of part of compounds is superior to that of a control drug.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a series of 15-membered ring quadruple lactone derivatives with neoantimycin mother nucleus structures, a preparation method of the 15-membered ring quadruple lactone derivatives and application of the 15-membered ring quadruple lactone derivatives in antitumor drugs, wherein the 15-membered ring quadruple lactone derivatives are generated by feeding chemical precursors in the fermentation process of streptomyces S.conglobatusATCC 31005. The compound is a fifteen-membered ring quadruple lactone derivative, the C-2 position of the derivative is connected with a carbonyl group or a hydroxyl group, the C-4 position and the C-9 position are substituted by aliphatic chains with different lengths, and the C-6 position of the derivative is connected with a benzoic acid group containing F atoms or hydroxyl groups. The compounds have obvious tumor cell proliferation inhibition activity on colorectal cancer cells and lung cancer cells, the inhibition activity is equivalent to that of a control drug oxaliplatin, and the compounds have weak toxicity on non-cancer cell strains. A novel lead compound is provided for research and development of novel antitumor drugs, and the compound is expected to be developed into a tumor inhibitor.

The utility model discloses a central medicine supply system in the technical field of circuit board manufacturing, and aims to solve the problems that in the prior art, the liquid level identification capability of liquid medicine is poor, and the function of controlling overflowing of the liquid medicine needs to be enhanced urgently. The method comprises the steps that a non-contact liquid level meter is adopted to detect the liquid level of a pesticide supply barrel, the non-contact liquid level meter is in signal connection with a control background, anti-overflow control can be conducted in advance, and data integration and analysis can be conducted in the later period; the non-contact liquid level meter is not in direct contact with the liquid medicine, so that the failure probability is reduced; on the basis that a non-contact liquid level meter is adopted to replace a traditional scheme, the height difference is designed for communication points at the two ends of a conveying pipeline, and a liquid medicine lifting pump is used for driving liquid medicine to overcome gravity to be conveyed to a medicine supply barrel; the liquid medicine in the conveying pipeline and part of the liquid medicine exceeding the first warning liquid level in the medicine supply barrel flow back into the liquid medicine storage barrel by means of gravity, and the overflow condition is prevented in a high-reliability mode.

Provided herein are novel docking peptides and antibody-based drug conjugates that include such docking peptides. In embodiments, the subject docking peptide allows for the controlled attachment of one or more drug moieties and a tumor targeting moiety that allows for the targeting of the drug moiety to the tumor microenvironment.In some embodiments, the antibody-based drug conjugates provided herein advantageously allows for enhanced targeted delivery of a drug payload having a controlled drug-to-antibody ratio (DAR) to a target site.

The present application relates to tap water production technical field, disclose a kind of dosing control method and system based on floc fractal dimension, its basic concept is: the one-dimensional fractal dimension and two-dimensional fractal dimension of floc in flocculation sedimentation tank are collected;When two-dimensional fractal dimension falls in the second threshold range, maintain current dosing amount;When one-dimensional fractal dimension is greater than the maximum of first threshold range and two-dimensional fractal dimension falls outside the second threshold range, reduce current dosing amount;When one-dimensional fractal dimension falls less than the minimum of first threshold range and two-dimensional fractal dimension falls outside the second threshold range, increase current dosing amount.The dosing control method based on floc fractal dimension provided in the present application, with two-dimensional fractal dimension of floc as benchmark and combining one-dimensional fractal dimension to adjust dosing amount, break through the limitation that conventional dosing optimization method must detect numerous external influencing factors and narrow medicament application range, shorten lag time, enhance the dynamic characteristics of control system.

The present application relates to a kind of two-edged needle medicinal materials and its preparation fast identification method, the preparation is containing two-edged needle Chinese medicine preparation such as Huatou Fengtongbao tablet, Huatou Fengtongbao capsule, two-edged needle analgesic tablet, the method includes the respective preparation of each test solution of the sample, then each test solution is spotted on the same silica gel G thin layer plate, using the uplink development method, with volume ratio 12:1:4:0.1 of petroleum ether-cyclohexane-ethyl acetate-glacial acetic acid as developing agent, development, take out, natural cool dry, under the inspection of ultraviolet light, in the chromatogram of test sample, in the corresponding position with the chromatogram of control drug material, same color fluorescent spot is shown.The present application can be used for the fast identification of two-edged needle medicinal materials and related preparation, and compared with the existing identification technology of two-edged needle and its preparation, no toxic organic solvent is used, with the advantages of simple, fast, environmental protection, green, result exclusive, accurate, controllable operation method.

The invention discloses a panchromatic up-conversion single nanocrystal excited by single wavelength as well as preparation and application of the panchromatic up-conversion single nanocrystal. And the up-conversion single nanocrystalline rare earth is doped with up-conversion luminescent nanoparticles UCNPs. The structural composition of the UCNPs is NaYbF4: Er NaYbF4 NaYbF4: Yb, Tm, the UCNPs is realized by constructing a core / shell / shell structure, and the reasonably designed architecture modulates the excitation power density by utilizing a photon-level dependent up-conversion process, so that the emission of green light, red light and blue light is realized. Along with the increase of the power density of the 980nm continuous wave laser, the emission color is systematically changed from green to red and finally to blue. The invention provides a simplified but highly universal excitation scheme for complete RGB adjustability, and has wide application prospects in the fields of advanced high-resolution color displays, anti-counterfeiting, multifunctional biological probes, drug controlled release and the like.

Drug delivery devices and methods of controlled drug delivery to a patient are provided. The drug delivery device may include one or two microchip elements, each of which has a body portion with one or more drug release apertures in fluid communication with at least one containment reservoir. The drug release apertures are closed off by one or more reservoir caps which can be electrically activated to open the drug release apertures. The drug delivery device also includes (i) a drug formulation disposed in the at least one containment reservoir, and (ii) at least one drug-permeable membrane. In some cases, an outer housing is spaced a distance from an exterior wall of the body portion of the microchip element, the outer housing includes the at least one drug-permeable membrane, and a depot space is defined between the drug-permeable membrane and the exterior wall of the body portion of the microchip element.

The present invention relates to the technical field of heterocyclic compound drugs and their preparation and application, and specifically to a tropane alkaloid composition for the treatment of COPD and its application. The composition combines tropane alkaloids, mannose-6-phosphate and polylactic acid-glycolic acid copolymer, and is constructed into a nanocomposite by nanoparticle preparation technology for aerosol inhalation administration. The composition aims to solve the problems of low bioavailability and lack of targeting in conventional administration of tropane alkaloids. Targeted delivery is achieved by introducing mannose-6-phosphate into the surface of nanoparticles, promoting drug enrichment in the lungs, and using polylactic acid-glycolic acid copolymer to control drug release, thereby increasing local drug concentration and therapeutic efficacy in the lungs.

The invention discloses ultrasonic controlled-release hydrogel as well as a preparation method and application thereof, and relates to the technical field of medical instruments. The hydrogel provided by the invention can realize ultrasonic controlled release, can realize effective control of drug release, can adjust the dosage according to clinical requirements, and improves the clinical transformation potential of a drug controlled release system. The composition is especially suitable for comprehensive immunoregulation of various pathogenic factors of chronic wounds. The preparation method provided by the invention is simple and easy to implement, low in cost and good in biological safety.

The invention belongs to the technical field of biomedical materials, and particularly relates to a temperature-sensitive estradiol hydrogel composition, a preparation method and application. According to the composition, a temperature-sensitive responsive network is constructed by introducing a PCL-PEG-PCL triblock copolymer, modified chitosan, a penetration enhancer and a buffer regulation system, so that rapid gelling, controlled-release drug delivery and good retention under a body temperature condition are realized. Through systematic contrast experiments with a plurality of contrast samples, evaluation is carried out from four aspects of gelling performance, drug release behavior, degradation residual rate and adhesiveness, and results show that the composition in a preferable ratio has the comprehensive advantages of good gel stability, long drug release period, good biodegradability, lasting uterine cavity adhesion and the like; good post-operation anti-adhesion and local drug delivery application prospects are realized.

This invention provides a liquid composition for topical and transdermal drug delivery, comprising a polymethacrylate at >5% weight, a humectant, a plasticizer, and a solvent. Optionally, it includes a permeation enhancer and / or a drug. Upon application and rapid drying, the composition forms a durable, non-sticky, non-transferable film that enables controlled drug release through the skin or retention at the skin surface.

The method comprises the following steps: preparing a first test solution, a second test solution, a third test solution, a reference medicinal material solution and a reference substance solution, sampling the solutions on a silica gel G thin-layer plate, and identifying notopterygium root, radix angelicae pubescentis, ligusticum, ligusticum wallichii, divaricate saposhnikovia root and liquorice. According to the identification method of the notopterygium root-containing dampness-clearing decoction, the first test solution for simultaneously identifying notopterygium root, radix angelicae pubescentis, ligusticum and ligusticum wallichii, the second test solution for identifying divaricate saposhnikovia root and the third test solution for identifying liquorice are obtained through a specific extraction process, so that the detection efficiency is greatly improved.

The invention provides composite hydrogel, photo-thermal response drug release composite hydrogel as well as a preparation method and application of the photo-thermal response drug release composite hydrogel, and belongs to the technical field of biomedical materials. The hydrogel is constructed by taking methylacryloyl gelatin as a matrix and combining lauric acid microspheres carrying an osteogenesis promoting drug baicalin, a reduced graphene oxide photothermal agent and a photoinitiator LAP. Under the irradiation of near-infrared light, the hydrogel can realize local mild temperature rise, induce the lauric acid microspheres to generate solid-liquid phase change, release the entrapped osteogenesis promoting drug as required, realize the synergistic effect of photothermal therapy and controlled release of the drug, and have a good osteogenesis repair effect. The hydrogel has good mechanical properties, biocompatibility and degradability, can be used for local treatment of bone defect parts, and effectively promotes regeneration and repair of oral and maxillofacial bone tissues. The invention provides a novel controllable and efficient treatment thought for bone tissue engineering and regenerative medicine.

The invention belongs to the technical field of medicines, and particularly relates to a tanshinone and salvianolic acid compound molecular compatibility composition for regulating and controlling the balance relation of DNMTs / TET2 and application of the tanshinone and salvianolic acid compound molecular compatibility composition. An in-vitro cell model proves that the composition with specific compatibility can synergistically regulate the expression of DNMTs and TET2 and recover the balance relation of DNMTs and TET2, so that the abnormal DNA methylation state is reversed, the normal expression of related genes is recovered, and the composition can be used for preparing the medicine for preventing or treating cardiovascular diseases related to DNA methylation abnormity. The molecular compatibility composition for balance regulation and control of key targets is created for the first time, has the advantages of clear component compatibility, clear action targets and synergistic interaction, and provides a new choice for developing novel epigenetic regulation and control drugs.

The invention discloses a method for photocatalytic synthesis of a 2, 3-dihydrobenzopyran-4-ketone compound and application of the 2, 3-dihydrobenzopyran-4-ketone compound, a triplet excitation state with a double-free-radical characteristic is formed after photoexcitation of a chromone compound, and the triplet excitation state can be subjected to hydrogen atom transfer with various substrates such as ethers, esters, alcohols, alkanes, sulfides, amines and aryl phosphine compounds, so that the 2, 3-dihydrobenzopyran-4-ketone compound is obtained. And carrying out Giese addition on the generated free radicals and an unexcited chromone compound to obtain a target product. Further biological activity evaluation shows that part of products obtained in the invention show good inhibitory activity on tobacco mosaic viruses, and the good protective activities of target compounds 3i and 4b are 67.77% and 63.63% respectively when the concentration is 500mg / L, which are equivalent to 63.83% of a control drug ningnanmycin. Therefore, the compound not only is green and efficient in synthesis method, but also has potential application value in the aspects of agricultural disease control and structure protection research.

The application discloses an electrically-controlled drug-loaded hot compress patch, a control circuit and a control method. The control circuit comprises a drug-loaded hot compress patch and a controller. The drug-loaded hot compress patch and the controller are connected. The drug-loaded hot compress patch comprises a drug-loaded layer, a heating layer and a fixing belt. The heating layer is arranged on the drug-loaded layer. The fixing belt is arranged on the heating layer. The drug type of the drug-loaded layer is selected based on user demand. The drug-loaded layer and the heating layer are detachably connected. A plurality of electric heating patches are arranged on the heating layer. The heating layer is used for heating the drug-loaded layer. The fixing belt is used for fixing the drug-loaded layer to the human skin. The controller controls the electric heating patches in the heating layer based on the effective release temperature of the drug on the drug-loaded layer.